# Study Evaluating EKB-569 in Advanced Colorectal Cancer

> **NCT00072748** · PHASE2 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 63 (actual)

## Conditions studied

- Colorectal Neoplasms
- Colonic Neoplasms
- Rectal Neoplasms

## Interventions

- **DRUG:** EKB-569

## Key facts

- **NCT ID:** NCT00072748
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** 2004-10
- **Final completion:** 2004-10
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2009-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00072748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00072748, "Study Evaluating EKB-569 in Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00072748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*